Cetuximab plus Irinotecan as third line chemotherapy for metastatic colorectal cancer

類似資料

• Regorafenib versus Cetuximab plus Irinotecan in Third-line Metastatic Colorectal Cancer in Iran: A Model-based Cost-utility Analysis
  著者:: Meysam Seyedifar, 等
  出版事項: (2024-10-01)
• EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer
  著者:: Frifeldt Sanne K, 等
  出版事項: (2011-03-01)
• Panitumumab versus cetuximab in combination with irinotecan in refractory metastatic colorectal cancer
  著者:: Maria Ignez Freitas Melro Braghiroli, 等
  出版事項: (2024-01-01)
• Cetuximab therapy in first-line metastatic colorectal cancer and intermittent palliative chemotherapy: review of the COIN trial.
  著者:: Adams, R, 等
  出版事項: (2008)
• First‐line therapy of bevacizumab plus chemotherapy versus cetuximab plus chemotherapy for metastatic colorectal cancer patients with mucinous adenocarcinoma or mucinous component
  著者:: Yu‐Wen Zhou, 等
  出版事項: (2021-05-01)